Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Ambac Financial Group, Inc. (NASDAQ: AMBC) shares declined 2.64 percent to close at $30.20 a share Friday. The stock traded between $29.50 and $31.04 on volume of 1.61 million shares traded. Analysts at MKM Partners have recently downgraded the company's rating to "sell" from "neutral". Shares of Ambac Financial Group have gained approximately 23.0 percent year-to-date.
Find out more about Ambac Financial Group including full access to the free equity report at:
www.RDInvesting.com/AMBC
On Assignment, Inc. (NYSE: ASGN) shares declined 1.01 percent to close at $36.14 a share Friday. The stock traded between $35.80 and $37.10 on volume of 247,438 shares traded. Analysts at Jefferies maintain a "buy" rating on the company with a price target of $40.00. Shares of On Assignment have gained approximately 3.0 percent year-to-date.
Find out more about On Assignment including full access to the free equity report at:
www.RDInvesting.com/ASGN
Ciena Corporation (NYSE: CIEN) shares declined 0.80 percent to close at $22.24 a share Friday. The stock traded between $21.90 and $22.50 on volume of 4.63 million shares traded. Analysts at RBC Capital Markets have recently downgraded the company's rating to "sector perform" from "outperform". Shares of Ciena have fallen approximately 7.0 percent year-to-date.
Find out more about Ciena including full access to the free equity report at:
www.RDInvesting.com/CIEN
Metabolix, Inc. (NASDAQ: MBLX) shares declined 14.29 percent to close at $1.20 a share Friday. The stock traded between $1.10 and $1.28 on volume of 405,500 shares traded. Analysts at Ardour Capital have recently downgraded the company's rating to "hold" from "accumulate". Shares of Metabolix have fallen approximately 5.0 percent year-to-date.
Find out more about Metabolix including full access to the free equity report at:
www.RDInvesting.com/MBLX
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
[email protected]